Search Results - "Yamada, Reiko E."

A Phase I Dose-Finding Trial of Recombinant Interleukin-21 and Rituximab in Relapsed and Refractory Low Grade B-cell Lymphoproliferative Disorders by TIMMERMAN, John M, BYRD, John C, ANDORSKY, David J, YAMADA, Reiko E, KRAMER, Janet, MUTHUSAMY, Natarajan, HUNDER, Naomi, PAGEL, John M

“…We conducted a phase I study to determine the safety, maximum-tolerated dose (MTD), and efficacy of weekly bolus recombinant human interleukin-21 (rIL-21) plus…”
Get full text

Programmed Death Ligand 1 Is Expressed by Non―Hodgkin Lymphomas and Inhibits the Activity of Tumor-Associated T Cells by ANDORSKY, David J, YAMADA, Reiko E, SAID, Jonathan, PINKUS, Geraldine S, BETTING, David J, TIMMERMAN, John M

“…Programmed death ligand 1 (PD-L1) is expressed on antigen-presenting cells and inhibits activation of T cells through its receptor PD-1. PD-L1 is aberrantly…”
Get full text

An HK2 Antisense Oligonucleotide Induces Synthetic Lethality in HK1 - HK2 + Multiple Myeloma by Xu, Shili, Zhou, Tianyuan, Doh, Hanna M, Trinh, K Ryan, Catapang, Art, Lee, Jason T, Braas, Daniel, Bayley, Nicholas A, Yamada, Reiko E, Vasuthasawat, Alex, Sasine, Joshua P, Timmerman, John M, Larson, Sarah M, Kim, Youngsoo, MacLeod, A Robert, Morrison, Sherie L, Herschman, Harvey R

“…Although the majority of adult tissues express only hexokinase 1 (HK1) for glycolysis, most cancers express hexokinase 2 (HK2) and many coexpress HK1 and HK2…”
Get full text

89Zr-ImmunoPET Shows Therapeutic Efficacy of Anti-CD20-IFNα Fusion Protein in a Murine B-cell Lymphoma Model by Zettlitz, Kirstin A, Salazar, Felix B, Yamada, Reiko E, Trinh, K Ryan, Vasuthasawat, Alex, Timmerman, John M, Morrison, Sherie L, Wu, Anna M

“…Antibody-mediated tumor delivery of cytokines can overcome limitations of systemic administration (toxicity, short half-lives). Previous work showed improved…”
Get full text

Hypophosphatemia Due to Increased Effector Cell Metabolic Activity Is Associated with Neurotoxicity Symptoms in CD19-Targeted CAR T-cell Therapy by Tang, Jack Pengfei, Peters, Cole W, Quiros, Crystal, Wang, Xiaoyan, Klomhaus, Alexandra M, Yamada, Reiko E, Timmerman, John M, Moore, Theodore B, Nowicki, Theodore S

“…A major complication of chimeric antigen receptor (CAR) T-cell therapy is immune effector cell-associated neurotoxicity syndrome (ICANS), which presents as…”
Get more information

Augmenting major histocompatibility complex class I expression by murine tumors in vivo enhances antitumor immunity induced by an active immunotherapy strategy by Merritt, Robert E, Yamada, Reiko E, Crystal, Ronald G, Korst, Robert J

“…Tumors down-regulate major histocompatibility complex class I expression, escaping recognition by the cellular immune response. We hypothesized that…”
Get full text

18F-labeled anti-human CD20 cys-diabody for same-day immunoPET in a model of aggressive B cell lymphoma in human CD20 transgenic mice by Zettlitz, Kirstin A., Tavaré, Richard, Tsai, Wen-Ting K., Yamada, Reiko E., Ha, Noel S., Collins, Jeffrey, van Dam, R. Michael, Timmerman, John M., Wu, Anna M.

“…Purpose Metabolic imaging using [ 18 F]FDG is the current standard for clinical PET; however, some malignancies (e.g., indolent lymphomas) show low avidity for…”
Get full text

Anti-CD20-interferon-β fusion protein therapy of murine B-cell lymphomas by Trinh, Kham R, Vasuthasawat, Alex, Steward, Kristopher K, Yamada, Reiko E, Timmerman, John M, Morrison, Sherie L

“…Type I interferons (IFNα/β) are cytokines with a broad spectrum of antitumor activities including antiproliferative, proapoptotic, and immunostimulatory…”
Get full text

Maleimide conjugation markedly enhances the immunogenicity of both human and murine idiotype-KLH vaccines by Kafi, Kamran, Betting, David J., Yamada, Reiko E., Bacica, Michael, Steward, Kristopher K., Timmerman, John M.

“…The collection of epitopes present within the variable regions of the tumor-specific clonal immunoglobulin expressed by B cell lymphomas (idiotype, Id) can…”
Get full text

Intratumoral But Not Systemic Delivery of CpG Oligodeoxynucleotide Augments the Efficacy of Anti-CD20 Monoclonal Antibody Therapy Against B Cell Lymphoma by BETTING, David J, YAMADA, Reiko E, KAFI, Kamran, SAID, Jonathan, VAN ROOIJEN, Nico, TIMMERMAN, John M

“…The anti-CD20 monoclonal antibody rituximab (Rituxan) has become a mainstay in the treatment of B cell non-Hodgkin lymphomas. The mechanisms of action for…”
Get full text

Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivo by Franki, Suzanne N., Steward, Kristopher K., Betting, David J., Kafi, Kamran, Yamada, Reiko E., Timmerman, John M.

“…The in vitro priming of tumor-specific T cells by dendritic cells (DCs) phagocytosing killed tumor cells can be augmented in the presence of antitumor…”
Get full text

Combination of Cyclophosphamide, Rituximab, and Intratumoral CpG Oligodeoxynucleotide Successfully Eradicates Established B cell Lymphoma by BETTING, David J, HURVITZ, Sara A, STEWARD, Kristopher K, YAMADA, Reiko E, KAFI, Kamran, ROOIJEN, Nico Van, TIMMERMAN, John M

“…Rituximab plus chemotherapy is standard therapy for patients with non-Hodgkin B cell lymphoma, but often complete response or cure is not achieved. Toll-like…”
Get full text

Cisplatin augments cytotoxic T-lymphocyte–mediated antitumor immunity in poorly immunogenic murine lung cancer by Merritt, Robert E, Mahtabifard, Ali, Yamada, Reiko E, Crystal, Ronald G, Korst, Robert J

“…Many tumors are poorly immunogenic and resistant to cytotoxic T-lymphocyte–mediated cell lysis. Because cisplatin has been demonstrated to increase tumor cell…”
Get full text

In vivo gene transfer of pigment epithelium-derived factor inhibits tumor growth in syngeneic murine models of thoracic malignancies by Mahtabifard, Ali, Merritt, Robert E., Yamada, Reiko E., Crystal, Ronald G., Korst, Robert J.

“…Pigment epithelium-derived factor is known to be an inhibitor of angiogenesis. We hypothesized that in vivo gene transfer of pigment epithelium-derived factor…”
Get full text

Effect of inhibition of multiple steps of angiogenesis in syngeneic murine pleural mesothelioma by Merritt, Robert E., Yamada, Reiko E., Wasif, Nabil, Crystal, Ronald G., Korst, Robert J.

“…Angiogenesis is a multistep process in which the endothelial cell plays a pivotal role. We hypothesized that the combination of two antiangiogenic agents with…”
Get full text

In Vivo Efficacy of Anti-CD20-Interferon-Gamma Fusion Protein Against Syngeneic B Cell Lymphoma Is Mediated By Natural Killer Cells by Vasuthasawat, Alex, Yamada, Reiko E, Trinh, Kham R, Rokni, Neiki, Morrison, Sherie L, Timmerman, John M.

“…Background: The interferons, including IFNα/IFNβ (type I) and IFNγ (type II) are essential mediators of anti-cancer immunity. To achieve efficient targeting of…”
Get full text

89Zr-ImmunoPET shows therapeutic efficacy of anti-CD20 interferon-α fusion protein in a murine B-cell lymphoma model by Zettlitz, Kirstin A, Salazar, Felix B, Yamada, Reiko E, Trinh, K Ryan, Vasuthasawat, Alex, Timmerman, John M, Morrison, Sherie L, Wu, Anna M

“…Antibody-mediated tumor delivery of cytokines can overcome limitations of systemic administration (toxicity, short half-lives). Previous work showed improved…”
Get full text

IL-1 receptor antagonist for prevention of severe immune effector cell-associated neurotoxicity syndrome by Oliai, Caspian, Crosetti, Anna, De Vos, Sven, Eradat, Herbert, Mead, Monica Diane, Larson, Sarah Marie, Tsai, Steven, Liu, Annabel, Khachatrian, Gina, Hannigan, Christopher, Yamada, Reiko E., Rokni, Neiki, Timmerman, John

“…Abstract only 7566 Background: Progress in chimeric antigen receptor (CAR) T-cell therapy has included reduction in life-threatening toxicity. Rates of severe…”
Get full text

Ibrutinib plus anti-CD20-interferon alpha fusion protein for treatment of B cell lymphomas by Kendle, Ryan F., Kimaiyo, Davis Kipkemboi, Yamada, Reiko E, Young, Patricia, Vasuthasawat, Alex, Trinh, Ryan K, Morrison, Sherie L, Timmerman, John

“…Abstract only…”
Get full text

Antibody-Interferon-Alpha Fusion Protein Therapy for the Treatment of B-Cell Non-Hodgkin Lymphoma: Enhanced ADCC, Inhibition of Proliferation, and In Vivo Eradication of CD20+ Human Lymphomas by Timmerman, John M., Steward, Kristopher K, Yamada, Reiko E, Young, Patricia A, Minning, Dena M., Sachdev, Raj K, Gresser, Michael J, Khare, Sanjay D, Morrison, Sherie L

“…Background: Interferon-alpha (IFNα) is a pleiotrophic cytokine with direct anti-tumor and immunostimulatory effects. Currently IFNα is approved for the…”
Get full text